Novartis pledges $250M in R&D funding for neglected tropical diseases, malaria
Over the next five years, Novartis is pledging to pour $250 million into R&D for new treatments of neglected tropical diseases and malaria — with the ultimate goal of eliminating these diseases.
“Over the past decade, great progress has been made against NTDs, but there is still a lot more work to be done,” CEO Vas Narasimhan said in a statement.
About 1.7 billion people still suffer from NTDs around the world, mostly in impoverished areas, and while malaria doesn’t fall in the NTD category, it still affects 241 million people and kills hundreds of thousands of children every year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.